首页> 外文期刊>European Journal of Pharmacology: An International Journal >S-15176 inhibits mitochondrial permeability transition via a mechanism independent of its antioxidant properties.
【24h】

S-15176 inhibits mitochondrial permeability transition via a mechanism independent of its antioxidant properties.

机译:S-15176通过独立于其抗氧化特性的机制抑制线粒体通透性转变。

获取原文
获取原文并翻译 | 示例
           

摘要

Mitochondrial Ca(2+) accumulation can induce a sudden increase in the permeability of the inner membrane. This phenomenon is due to the generation of a large nonselective ion channel, termed the permeability transition pore (PTP), which contributes to cellular injury during ischemia and reperfusion. Inhibition of PTP generation constitutes a relevant pharmacological target to protect a cell from death. In this study, we examined the effect of S-15176 ((N-[(3,5-di-tertiobutyl-4-hydroxy-1-thiophenyl)]-3-propyl-N'-(2,3,4-trime thoxybenzyl)piperazine), a novel anti-ischemic agent, on PTP in rat liver mitochondria. S-15176 prevented PTP opening generated by various triggering agents, as attested by the concentration-dependent inhibition of mitochondrial swelling, of mitochondrial membrane potential dissipation and of NADPH oxidation. These effects were associated with an increase in the Ca(2+) loading capacity of mitochondria. S-15176 was a strong inhibitor of lipid peroxidation, but experiments with another trimetazidine derivative devoid of antioxidant activity indicated that this activity was not essential to the inhibitory effect. Binding studies demonstrated that [3H]S-15176 bound to mitochondrial binding sites, especially those localized in the inner membrane. These sites were shared by several well-known inhibitors of PTP opening. These results demonstrate that the mechanism by which S-15176 protects mitochondria against the deleterious effects of ischemia-reperfusion involves inhibition of PTP opening and provide evidence that the drug operates through low structural specificity binding sites located in the inner mitochondrial membrane.
机译:线粒体Ca(2+)积累可以诱导内膜的通透性突然增加。这种现象是由于产生了一个大的非选择性离子通道,称为通透性转换孔(PTP),它在局部缺血和再灌注过程中导致了细胞损伤。抑制PTP生成构成了保护细胞免于死亡的相关药理学目标。在这项研究中,我们检查了S-15176((N-[(3,5-二叔丁基-4-羟基-1-硫代苯基)]-3-丙基-N'-(2,3,4-三甲氧基苄基哌嗪)是一种新型的抗缺血药物,对大鼠肝线粒体中的PTP具有抑制作用.S-15176阻止了各种触发剂产生的PTP开放,这是由浓度依赖性抑制线粒体肿胀,线粒体膜电位消散和这些作用与线粒体Ca(2+)负载量的增加有关。S-15176是脂质过氧化作用的强抑制剂,但对另一种没有抗氧化活性的曲美他嗪衍生物进行的实验表明,该活性并不强结合研究表明,[3H] S-15176与线粒体结合位点结合,尤其是位于内膜的结合位点,这些位点被几种著名的PTP开放抑制剂所共有,这些结果证明了其机理。通过whi ch S-15176保护线粒体免受缺血再灌注的有害影响,涉及抑制PTP的开放,并提供证据表明药物通过位于线粒体内膜的低结构特异性结合位点起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号